Account

Company

  Menu
Large Image

Description

This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications.

• Third edition of the first ever book published on pediatric psychopharmacology from renowned editors.

• Incorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior.

• Addresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD.

• Features many tables, figures and pictorials, making it highly accessible and reader friendly.

Tag This Book

This Book Has Been Tagged
It hasn't. Be the first to tag this book!

Our Recommendation

Track It. This book has been $92.00 within the past year.

Notify Me When The Price...

  • $
  • If I'm already tracking this book...

to track this book on eReaderIQ.

Track These Authors

to track David Rosenberg on eReaderIQ.

  • to be notified each time the price drops on any book by David Rosenberg.
  • to stop tracking David Rosenberg.

to track Samuel Gershon on eReaderIQ.

  • to be notified each time the price drops on any book by Samuel Gershon.
  • to stop tracking Samuel Gershon.

Price Summary

  • We started tracking this book on July 26, 2013.
  • This book was $59.49 when we started tracking it.
  • The price of this book has changed 184 times in the past 3,899 days.
  • The current price of this book is $100.00 last checked 53 minutes ago.
  • This book is at its lowest price in the past 90 days.
  • This lowest price this book has been offered at in the past year is $92.00.
  • The lowest price to date was $52.72 last reached on March 13, 2019.
  • This book has been $52.72 one time since we started tracking it.
  • The highest price to date was $115.50 last reached on September 5, 2021.
  • This book has been $115.50 2 times since we started tracking it.

Additional Info

  • Publication Date: February 10, 2012
  • Text-to-Speech: Enabled
  • Lending: Disabled
  • Print Length: 474 Pages
  • File Size: 3,149 KB

We last verified the price of this book about 53 minutes ago. At that time, the price was $100.00. This price is subject to change. The price displayed on the Amazon.com website at the time of purchase is the price you will pay for this book. Please confirm the price before making any purchases.